Skip to content
Politically.com Search all
Menu

2025 · 1st Quarter (Jan 1 - Mar 31)

AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS

Filed by AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS.

Open official filing
Source: Lobbying Disclosure APIRecently refreshed. 2026-08-03 06:26:15 UTC.

Source-reported fields

Filing overview

Type
1st Quarter - Report
Posted
Apr 17, 2025
Income
Not reported
Expenses
$220,000.00
Filing UUID
016d8cea-79f7-4558-9aa5-75df9a48ba25
Termination date
Not reported

Expense method: A

Literal source text

Lobbying issues and bill citations

HCR · Health Issues

Issues related to drug pricing, drug shortages, drug importation plans, and the drug supply chain (generally, no specific legislation). Issues related to telehealth and pharmacist provision of testing and vaccination (generally, no specific legislation). Patient access to pharmacist provided services for respiratory illnesses, initiation of oral antivirals, buprenorphine, and other pharmacist services authorized under state law (generally, no specific legislation). Issues related to healthcare workforce shortages (generally, no specific legislation). Provisions related to site neutral payments (generally, no specific legislation). The Dr. Lorna Breen Health Care Provider Protection Reauthorization Act (H.R. 929/S. 266), provisions related to supporting health workers mental health and well-being. Issues related to implementation of the Inflation Reduction Act (generally, no specific legislation).

Literal federal measure citations: H.R. 929, S. 266

MMM · Medicare/Medicaid

The Equitable Community Access to Pharmacist Services Act, including reimbursement for pharmacist provision of testing and vaccination. Issues related to telehealth reimbursement and virtual supervision flexibilities for pharmacist services with CMS (generally, no specific legislation).

PHA · Pharmacy

Issues related to FDA authority to manage drug shortages, regulation of pharmacy compounding, and implementation of the Drug Quality and Security Act. Issues related to pharmacy benefit manager (PBM) abuses and transparency (generally, no specific legislation). Issues related to 340B program nondiscrimination and contract pharmacy arrangements (generally, no specific legislation). Issues related to manufacturer attempts to undercut the 340B program (generally, no specific legislation). Issues related to pharmacy residency funding, including support for the Rebuild Americas Health Care Schools Act of 2024 (S. 5397/H.R. 10225). Issues related to drug price negotiations and patient out-of-pocket costs (generally, no specific legislation).

Literal federal measure citations: S. 5397, H.R. 10225

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.